No significant difference between advanced therapies for RA

Individualised care should be based on clinical judgement and consideration of patient preferences. INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. The goal of treatment is often remission […]

Read More…

Managing RA with DMARDs

This is the lay version of the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis using synthetic and biologic disease-modifying antirheumatic drugs. The original publication can be downloaded from the EULAR website: www.eular.org. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic […]

Read More…

People with early RA have signs of cardiovascular changes

Treatments for rheumatoid arthritis might also help to reduce cardiovascular damage INTRODUCTION Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. People with rheumatoid arthritis have an increased risk of […]

Read More…

Economic status, location, and healthcare system impact how well treatments work in trials

More consistent reporting of patient characteristics is needed across rheumatology trials. INTRODUCTION Rheumatic diseases affect people’s joints, bones, tendons, ligaments and muscles – and often also other organs. Many of these diseases are autoimmune conditions that cause inflammation in the body. There are more than 200 rheumatic diseases, including rheumatoid arthritis, osteoarthritis, psoriatic arthritis, spondyloarthritis, […]

Read More…

Managing RA with DMARDs

This is the lay version of the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis using synthetic and biologic disease-modifying antirheumatic drugs. The original publication can be downloaded from the EULAR website: www.eular.org. Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic […]

Read More…

Changes may be needed to improve the usefulness of remission definitions

Adapting the thresholds in the Boolean remission definition would improve patient evaluation. Introduction Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. The goal of treatment for rheumatoid arthritis is […]

Read More…

T2T in real-life helps people get to remission

Rheumatologists should follow a T2T-strategy in patients with both early and established rheumatoid arthritis. Introduction Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. ‘Treat to target’ (often shortened to […]

Read More…

Unclear benefit of Zostavax in people starting on tofacitinib

Zostavax may not provide adequate long-term protection in people taking tofacitinib for their rheumatoid arthritis. Introduction Rheumatoid arthritis is a chronic inflammatory disease that can affect a person’s joints, and may cause pain and disability. Rheumatoid arthritis affects people of all ages, and is more common in women than men. People with rheumatoid arthritis naturally […]

Read More…